• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RDNT

    RadNet Inc.

    Subscribe to $RDNT
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.

    IPO Year:

    Exchange: NASDAQ

    Website: radnet.com

    Recent Analyst Ratings for RadNet Inc.

    DatePrice TargetRatingAnalyst
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    8/12/2021Outperform → Market Perform
    Raymond James
    8/12/2021$39.00Overweight
    Barclays
    See more ratings